Failure to respond to standard wound care occurs when there are no measurable signs of healing for at least 30 consecutive days. Wounds must be evaluated at least every 30 days during HBOT. Below are the 15 CMS and most third-party payors approved and reimbursement indications for HBOT outcomes.
These payors and reimbursement indications range from the critical care inpatient to the ambulatory care self-referral:
Acute carbon monoxide intoxication
Acute traumatic peripheral ischemia. HBOT is a valuable treatment to be used in combination with accepted standard therapeutic measures when loss of function, limb or life is threatened.
Crush injuries and suturing of severed limbs. As in the previous conditions and outcomes, HBOT would be an adjunctive treatment when loss of function, limb or life is threatened.
9. Preparation and preservation of compromised skin grafts (not for primary management of wounds)
10. Chronic refractory osteomyelitis, unresponsive to conventional treatment
11. Osteoradionecrosis as an adjunct to conventional treatment
12. Soft tissue radionecrosis as an adjunct to conventional treatment
13. Cyanide poisoning
14. Actinomycosis, only as an adjunct outcome to conventional therapy when the disease process is refractory to antibiotics and surgical treatment
15. Diabetic wounds of the lower extremities in patients who meet the following criteria: a) Patient has type I or type II diabetes and has a lower extremity wound that is due to diabetes; b) Patient has a wound classified as Wagner grade III or higher; and c) Patient has failed an adequate course of standard wound therapy